过去一年中添加的文章，按日期排序

… of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the …

C Spalding, B Mountford… - Value in …, 2024 - valueinhealthjournal.com
23 天前 - … patient subgroups. Our analysis aimed to estimate the cost-effectiveness of apixaban
compared to rivaroxaban… from ARISTOPHANES subpopulations (obesity, polypharmacy, …
相关文章

Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.

D Basali, H Zureigat, DP Nurse, H Elmaleh, H Batah… - 2024 - ascopubs.org
26 天前 - … in NDMM patients and explore incidence of VTE, utility of SAVED and IMPEDE
scores, and patient safety. Methods: We retrospectively analyzed outcomes of NDMM patients …
相关文章

Comparison of two DCCV algorithms-rational versus maximum fixed energy (PROTOCOLENERGY trial)

L Rucki, O Jiravsky, R Miklik, J Chovancik, B Szmek… - Europace, 2024 - academic.oup.com
30 天前 - … The aim of this study was to compare the efficacy and safety of two different DCCV
algorithms, Rational and Maximum Fixed Energy, in achieving sinus rhythm after DCCV. The …
相关文章 所有 4 个版本

Rivaroxaban Versus Warfarin in the Treatment of Patients with Atrial Fibrillation and Previous Ischaemic Stroke/Tia-an Efficacy and Safety Evaluation

C You, C Guan, P Niu, N Zhao, X Dong, Y Lan, S Jiang - papers.ssrn.com
55 天前 - … rivaroxaban in 38 extremely obese patients (BMI >40 kg/m2 or >120 kg). They 282
… , safety, 434 and costs of rivaroxaban and warfarin among morbidly obese patients with atrial …
相关文章
[HTML] scirp.org

[HTML][HTML] Pharmacodynamic Study of Parallel Groups Comparing the Effect of Rivaroxaban 20 Mg (Laboratorios Leti, SAV) vs Rivaroxaban 20 Mg (Bayer Laboratories) …

ER de Roa, MG Yibirin, DR Matute… - International Journal of …, 2024 - scirp.org
95 天前 - … of the action of Rivaroxaban, we used the prothrombin time (PT); however… BMI,
and SBP/DBP level with a greater number of men in the Bayer group. The efficacy of rivaroxaban …
相关文章 所有 2 个版本

Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation

P Dobry, K McGrew, I Yun, R Heath, A Shafqat… - European Journal of …, 2024 - Springer
96 天前 - … However, incidence rates for stroke or systemic embolism and major bleeding were
lower in our study than what was observed in the obese cohort of the landmark rivaroxaban …
相关文章 所有 3 个版本

Venous thromboembolism-was is new in the revised AWMF guideline?

B Linnemann, KS Mühlberg… - Deutsche Medizinische …, 2024 - europepmc.org
118 天前 - … (BMI) of 40 kg/m². Weight restrictions are no longer recommended for apixaban and
rivaroxaban, … is recommended in the extremely obese and patients after bariatric surgery. In …
相关文章 所有 2 个版本

Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity

JD Sperry, A Loeb, MJ Smith, TB Brighton… - Journal of Thrombosis …, 2024 - Springer
118 天前 - … groups in patients receiving rivaroxaban or apixaban, … assessing rivaroxaban use
in patients with obesity, one … recurrence in those receiving rivaroxaban compared to warfarin. …
相关文章 所有 3 个版本
[PDF] casopisvnitrnilekarstvi.cz

[PDF][PDF] Doporučené dávkování antikoagulancií v době pandemie obezity

A Pilková - Vnitřní lékařství, 2024 - casopisvnitrnilekarstvi.cz
119 天前 - … dosing differences for patients with higher degree of obesity. Therapeutic dosing
of … obese patients with atrial fibrillation shows comparable efficacy and safety, rivaroxaban …
相关文章 所有 3 个版本
[PDF] ki.se

[图书][B] Monitoring of the oral anticoagulants apixaban and rivaroxaban to optimize individual safety and efficacy

F Al-Aieshy - 2024 - openarchive.ki.se
150 天前 - … A specific dose recommendation for obese patients may not be necessary given
that the concentrations were largely similar to those in matched normal weight …
相关文章